Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Galapagos NV
Galapagos NV
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant
The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Bespak and H&T Presspart announce availability of GMP pilot line for climate-friendly pMDIs
Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze
Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Axol Bioscience boosts its iPSC bioassay offering with Phenocell acquisition
The acquisition will extend Axol's range of iPSC-derived cell lines, including skin and retinal cells — while also expanding its drug discovery services
How AI and GenAI will revolutionise the healthcare industry
Artificial intelligence — and particularly its newest iteration, generative artificial intelligence (GenAI) — could bring significant changes to the way we live, work and...
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Galapagos and NovAliX enter integrated drug discovery collaboration
The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology
Research & Development
Galapagos expands fibrosis portfolio
Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development
Pharnext announces R&D agreement with Galapagos
The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications
Research & Development
Galapagos ends inflammation partnership with Janssen
Long-running alliance started in 2007
Research & Development
AbbVie and Galapagos to co-develop cystic fibrosis therapies
Firms aim to start Phase 1 trials at end of 2014
Research & Development
Galapagos appoints CEO of Service Division
David Smith returns to the Belgian firm in new role
Research & Development
Galapagos receives €2.5m grant for IBD research
IWT-funded project aims to identify new compounds for future treatment of IBD
Subscribe now